{"id":"W4412370560","doi":"10.1007/s40120-025-00784-0","title":"Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"EMD Serono; Idorsia Pharmaceuticals; Schweizerische Multiple Sklerose Gesellschaft; Ministry of Health, Labour and Welfare; Fondazione Cariplo; Multiple Sclerosis Society; Shionogi; Argenx; Atara Biotherapeutics; Genentech; Amicus Therapeutics; Novartis; Celgene; Ministry of Education, Culture, Sports, Science and Technology; BioCryst; Sanofi; GW Pharmaceuticals; TG Therapeutics; Samsung; Bristol-Myers Squibb; CSL Behring; Pfizer; Biogen; F. Hoffmann-La Roche; Greenwich Biosciences; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi Genzyme; Patient-Centered Outcomes Research Institute","keywords":"Medicine; Ofatumumab; Multiple sclerosis; Neurology; Natalizumab; Internal medicine; Dermatology; Immunology; Psychiatry; Rituximab; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001126,0.0001507158,0.0003513162,0.0001505408,0.0001397804,0.00001144653,0.00004561107,0.00008013425,0.00001142941],"category_scores_gemma":[0.0001216159,0.00009310288,0.00001873425,0.0001750448,0.0003010137,0.0000507974,0.00005023018,0.0003163702,0.00000101945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009838468,"about_ca_system_score_gemma":0.00002675078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000606778,"about_ca_topic_score_gemma":0.00008527913,"domain_scores_codex":[0.9990445,0.00009835608,0.0001467146,0.000324097,0.000140747,0.0002455829],"domain_scores_gemma":[0.9992557,0.0004090976,0.00003539032,0.0001829855,0.00005895265,0.00005791247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01458747,0.0002320955,0.9600598,0.00001630268,0.0001156903,0.000004954401,0.0002528781,0.000005042994,0.0001365328,0.00003337876,0.00003378165,0.02452205],"study_design_scores_gemma":[0.02758557,0.001623448,0.9696684,0.00008062757,0.00001335142,0.000001067455,0.00002259855,0.00005629909,0.00004706199,0.000009893219,0.0008171641,0.00007455365],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957148,0.0004122761,0.00001198339,0.002860778,0.00003550693,0.0005767004,0.00000520585,0.00002781451,0.0003549174],"genre_scores_gemma":[0.9958814,0.002366168,0.0001563126,0.00144892,0.000007960788,0.00001636706,0.000005499722,0.00001333977,0.0001040463],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0244475,"threshold_uncertainty_score":0.3796625,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02200023117692603,"score_gpt":0.2685536937391004,"score_spread":0.2465534625621743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}